ADMA Biologics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade ADMA Biologics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ADMA

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. 

CEO
Adam S. Grossman
CEOAdam S. Grossman
Employees
647
Employees647
Headquarters
Ramsey, New Jersey
HeadquartersRamsey, New Jersey
Founded
2004
Founded2004
Employees
647
Employees647

ADMA Key Statistics

Market cap
2.14B
Market cap2.14B
Price-Earnings ratio
15.25
Price-Earnings ratio15.25
Dividend yield
Dividend yield
Average volume
14.87M
Average volume14.87M
High today
$9.42
High today$9.42
Low today
$8.95
Low today$8.95
Open price
$9.15
Open price$9.15
Volume
7.31M
Volume7.31M
52 Week high
$25.67
52 Week high$25.67
52 Week low
$7.21
52 Week low$7.21

Stock Snapshot

ADMA Biologics(ADMA) stock is priced at $9.13, giving the company a market capitalization of 2.14B. It carries a P/E multiple of 15.25.

As of 2026-03-31, ADMA Biologics(ADMA) stock has fluctuated between $8.95 and $9.42. The current price stands at $9.13, placing the stock +2.0% above today's low and -3.1% off the high.

ADMA Biologics(ADMA) shares are trading with a volume of 7.31M, against a daily average of 14.87M.

In the last year, ADMA Biologics(ADMA) shares hit a 52-week high of $25.67 and a 52-week low of $7.21.

In the last year, ADMA Biologics(ADMA) shares hit a 52-week high of $25.67 and a 52-week low of $7.21.

ADMA News

Simply Wall St 17h
Assessing ADMA Biologics Valuation After Rebuttal To Short Seller Allegations

ADMA Biologics (ADMA) moved back into focus after its shares climbed about 11% following a detailed rebuttal to a short seller report that questioned ASCENIV de...

Assessing ADMA Biologics Valuation After Rebuttal To Short Seller Allegations
Benzinga 4d
What's Behind The Jump In Vor Biopharma Stock?

Vor Biopharma stock is among today’s top performers. What’s driving VOR stock higher? Vor Biopharma To Raise $75 Million Through Private Placement The clinical-...

What's Behind The Jump In Vor Biopharma Stock?
Benzinga 4d
ADMA Biologics Slams Short Seller Claims, Highlights Strong Demand

The report from Culper Research, released on Tuesday, alleges that ADMA Biologics has been misrepresenting its financial results and operating metrics. The fir...

ADMA Biologics Slams Short Seller Claims, Highlights Strong Demand

More ADMA News

TipRanks 4d
ADMA Biologics Issues Rebuttal to Short-Seller Allegations

The latest update is out from ADMA Biologics ( (ADMA) ). On March 27, 2026, ADMA Biologics issued a detailed rebuttal to a March 24, 2026 short-seller report f...

Simply Wall St 4d
ADMA Biologics Challenges Short Report As Valuation And Compliance Scrutinized

ADMA Biologics (NasdaqGM:ADMA) issued a public response to a short-seller report from Culper Research. The company disputed the accuracy of the allegations and...

ADMA Biologics Challenges Short Report As Valuation And Compliance Scrutinized
TipRanks 4d
Adma Biologics responds to short seller report by Culper Research

Adma Biologics (ADMA) responded to a report issued on March 24 by short seller Culper Research. The company said, “Following a detailed review of the Short Repo...

Benzinga 5d
Why Are Shares Of ADMA Biologics Falling Today?

ADMA Biologics, Inc. (NASDAQ:ADMA) shares are tumbling on Thursday after Cantor Fitzgerald downgraded the stock to Neutral. ADMA Biologics shares are approachin...

Why Are Shares Of ADMA Biologics Falling Today?
Benzinga 6d
Short Seller Report Alleges ADMA Biologics Financial Misrepresentation

• ADMA Biologics stock is testing key support levels. What’s pressuring ADMA? Culper Research Describes ADMA Short; Alleges Misreporting The report from Culper...

Short Seller Report Alleges ADMA Biologics Financial Misrepresentation

People also own

Based on the portfolios of people who own ADMA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.